|
1
|
Lustberg MB and Ramaswamy B: Epigenetic
therapy in breast cancer. Curr Breast Cancer Rep. 3:34–43. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang X, Yan L and Davidson NE: DNA
methylation in breast cancer. Endocr Relat Cancer. 8:115–127. 2001.
View Article : Google Scholar
|
|
3
|
Connolly R and Stearns V: Epigenetics as a
therapeutic target in breast cancer. J Mammary Gland Biol
Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Locke WJ and Clark SJ: Epigenome
remodelling in breast cancer: insights from an early in vitro model
of carcinogenesis. Breast Cancer Res. 14:2152012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, DeSantis C, Virgo K, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oikawa T: ETS transcription factors:
possible targets for cancer therapy. Cancer Sci. 95:626–633. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Galang CK, Muller WJ, Foos G, Oshima RG
and Hauser CA: Changes in the expression of many Ets family
transcription factors and of potential target genes in normal
mammary tissue and tumors. J Biol Chem. 279:11281–11292. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsu T, Trojanowska M and Watson DK: Ets
proteins in biological control and cancer. J Cell Biochem.
91:896–903. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li R, Pei H and Watson DK: Regulation of
Ets function by protein - protein interactions. Oncogene.
19:6514–6523. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seth A and Watson DK: ETS transcription
factors and their emerging roles in human cancer. Eur J Cancer.
41:2462–2478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghadersohi A and Sood AK: Prostate
epithelium-derived Ets transcription factor mRNA is overexpressed
in human breast tumors and is a candidate breast tumor marker and a
breast tumor antigen. Clin Cancer Res. 7:2731–2738. 2001.PubMed/NCBI
|
|
12
|
Sood AK, Saxena R, Groth J, et al:
Expression characteristics of prostate-derived Ets factor support a
role in breast and prostate cancer progression. Hum Pathol.
38:1628–1638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamada N, Tamai Y, Miyamoto H and Nozaki
M: Cloning and expression of the mouse Pse gene encoding a
novel Ets family member. Gene. 241:267–274. 2000.
|
|
14
|
Ghadersohi A, Odunsi K, Lele S, et al:
Prostate derived Ets transcription factor shows better
tumor-association than other cancer-associated molecules. Oncol
Rep. 11:453–458. 2004.
|
|
15
|
Schaefer JS, Sabherwal Y, Shi HY, et al:
Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF
controls cell proliferation and mammary tumor progression. J Biol
Chem. 285:11258–11269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sabherwal Y, Mahajan N, Helseth DL,
Gassmann M, Shi H and Zhang M: PDEF downregulates stathmin
expression in prostate cancer. Int J Oncol. 40:1889–1899.
2012.PubMed/NCBI
|
|
17
|
Ghoshal K and Bai S: DNA
methyltransferases as targets for cancer therapy. Drugs Today.
43:395–422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Acharya MR, Sparreboom A, Venitz J and
Figg WD: Rational development of histone deacetylase inhibitors as
anticancer agents: a review. Mol Pharmacol. 68:917–932. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsuzaki Y, Sowa Y, Hirose T, Yokota T
and Sakai T: Histone deacetylase inhibitors: promising agents for
‘gene-regulating chemoprevention’ and ‘molecular-targeting
prevention’ of cancer. Environ Health Prev Med. 8:157–160.
2003.
|
|
20
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Braiteh F, Soriano AO, Garcia-Manero G, et
al: Phase I study of epigenetic modulation with 5-azacytidine and
valproic acid in patients with advanced cancers. Clin Cancer Res.
14:6296–6301. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karahoca M and Momparler RL:
Pharmacokinetic and pharmacodynamic analysis of
5-aza-2′-deoxycytidine (decitabine) in the design of its
dose-schedule for cancer therapy. Clin Epigenetics. 5:32013.
|
|
23
|
Feldman RJ, Sementchenko VI, Gayed M,
Fraig MM and Watson DK: Pdef expression in human breast cancer is
correlated with invasive potential and altered gene expression.
Cancer Res. 63:4626–4631. 2003.
|
|
24
|
Ghadersohi A, Pan D, Fayazi Z, Hicks DG,
Winston JS and Li F: Prostate-derived Ets transcription factor
(PDEF) downregulates survivin expression and inhibits breast cancer
cell growth in vitro and xenograft tumor formation in vivo. Breast
Cancer Res Treat. 102:19–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oettgen P, Finger E, Sun Z, et al: PDEF, a
novel prostate epithelium-specific Ets transcription factor,
interacts with the androgen receptor and activates
prostate-specific antigen gene expression. J Biol Chem.
275:1216–1225. 2000. View Article : Google Scholar
|
|
26
|
Thompson HG, Harris JW, Wold BJ, Lin F and
Brody JP: p62 overexpression in breast tumors and regulation by
prostate-derived Ets factor in breast cancer cells. Oncogene.
22:2322–2333. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang M, Maass N, Magit D and Sager R:
Transactivation through Ets and Ap1 transcription sites determines
the expression of the tumor-suppressing gene maspin. Cell Growth
Differ. 8:179–186. 1997.PubMed/NCBI
|
|
28
|
Zhang M, Magit D and Sager R: Expression
of maspin in prostate cells is regulated by a positive Ets element
and a negative hormonal responsive element site recognized by
androgen receptor. Proc Natl Acad Sci USA. 94:5673–5678. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gros C, Fahy J, Halby L, et al: DNA
methylation inhibitors in cancer: recent and future approaches.
Biochimie. 94:2280–2296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marks PW: Decitabine for acute myeloid
leukemia. Expert Rev Anticancer Ther. 12:299–305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nebbioso A, Carafa V, Benedetti R and
Altucci L: Trials with ‘epigenetic’ drugs: an update. Mol Oncol.
6:657–682. 2012.
|
